Input 2020.12.17 07:51 | Revision 2020.12.17 08:00
–
The US International Trade Commission (ITC) ruled that “Daewoong Pharmaceutical violated Article 337 of the Customs Act” against the theft of botulinum strains and manufacturing technology between Medytox and Daewoong Pharmaceuticals on the 16th (local time).
The ITC issued an order to ban imports of Daewoong Pharmaceutical’s botulinum toxin product’Nabota’ for 21 months. Daewoong Pharmaceutical said, “We will apply for a temporary injunction against the 21-month injunction. We are confident that we will win the final victory by exercising the President’s veto and appealing to the US Federal Circuit Court of Appeals.”
In response, Medytox said, “In the past 33 years, only one case has been rejected by the US President of the ITC.”
–
– .
Related posts:
ByteDance may not have to sell TikTok after all - IT Pro - News
Cheerful AEX continues record series |reeks Financial
Promotional photos of Samsung Galaxy S23 series exposed, purple and green will become the main color...
BYD Unveils $233,450 Electric Supercar Competing with Ferrari and Lamborghini - Largest Seller of El...
